2. Identification of the Endocannabinoid System
In the late 1980s and early 1990s, Professor Mechoulam and his team discovered the endocannabinoid system, a complex network of receptors and signalling molecules that regulate a wide range of physiological processes. The ECS is a complex system of receptors, endocannabinoids, and enzymes that are involved in regulating various physiological processes, including pain, appetite, mood, and immune function. This groundbreaking discovery has led to the development of new drugs for a variety of medical conditions, including chronic pain, multiple sclerosis, and epilepsy.
3. Exploration of Cannabidiol (CBD)
Professor Mechoulam has been a pioneer in the study of cannabidiol (CBD), a non-psychoactive compound found in cannabis. His research has shown that CBD has significant therapeutic potential. The benefits of CBD research have found it supports the body across pain relief, anxiety and depression, epilepsy, sleep and various skin conditions. Professor Mechoulam also played a key role in the development of Epidiolex, the first FDA-approved CBD-based medication for the treatment of epilepsy.